(PharmaNewsWire.Com, October 03, 2018 ) Industry Outlook and Trend Analysis
The Liquid Biopsy Market is expected to gain considerable market share by 2025, while registering itself at a significant compound annual growth rate (CAGR) during the forecast period. Liquid biopsy is a rapidly emerging alternative for customary tumor biopsies, created out of the requirement to gain the most amounts of molecular data regarding cancer with minimal surgical invasion. With quick improvements in NGS technology, liquid biopsies are assessed to take prime position with regards to cancer related investigation and probe. Besides, with foreseen positive outcomes from various clinical trials for the advancement of these tests and resulting bigger scaled clinical trials exhibiting viability, it is likely that the testing procedure will serve a more extensive base of patient in atomic checking settings.
The advent of complete commercialization of liquid biopsies is anticipated to be significantly problematic. Three major applications of liquid biopsy can be therapy selection for other metastatic cancers, therapy selection tool for metastatic breast cancers, and molecular health monitoring. With the rising frequency of metastatic cancer over the globe, the therapy selection tool for metastatic breast cancers section is anticipated to hold an extensive share in the market all through the estimate time frame.
Sample Type Outlook and Trend Analysis
Because of the various previous applications and techniques for purification, blood sampling is the most commonly used example for liquid biopsy studies and product improvements. Circulating tumor cells, cell-free DNA and exosomes and in addition microvesicles can be recognized in blood test. This brings about higher rate of adoption of liquid biopsy through blood testing. The next generation sequencing (NGS) technology is used in this for identification of numerous transformations in various genes.
Biomaker Type Outlook and Trend Analysis
There are around 8-10 fluid biopsy tests on the basis of CTCs and ctDNA that are as of now commercialized. Moreover, more than 30 tests in view of each of the three of these biomarkers are in clinical improvement by some major market players. Commercialization of these tests in the offing is evaluated to profit the development of the general market.
Technology Outlook and Trend Analysis
Based on technology, single gene analysis and multi gene analysis are the two main techniques used. PCR-based sequencing is used for analysis of changes in disease specific genes though analysis of numerous diseases all the while can be completed by using the NGS multiplex testing. PCR microarray and NGS technology are both viewed as vital for examination of previously mentioned biomarkers to perform any liquid biopsy analysis.
Regional Outlook and Trend Analysis
North America was at the forefront of the market in 2016, trailed by Europe. The development of the area can be credited to recent regulatory approvals by CE for business application of these liquid biopsy tests. Nonetheless, Asia Pacific is probably going to enroll exceptional CAGR amid the gauge time frame as governments and organizations are endeavoring to continue developing growth predominance rates in the area under control. Japan, India, and China are the major contributing nations to the area's development.
Competitive Insights
The leading players in the market are Personal Genome Diagnostics, TrovaGene, Guardant Health, Raindance Technologies, Adaptive Biotechnologies, Qiagen, Cynvenio Biosystems Inc, Biocept and NeoGenomics. The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
